Publication: HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy
Open/View Files
Date
2008
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley-Blackwell
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Alexis, Frank, Pamela Basto, Etgar Levy-Nissenbaum, Aleksandar F. Radovic-Moreno, Liangfang Zhang, Eric Pridgen, Andrew Z. Wang, et al. 2008. “HER-2-Targeted Nanoparticle-Affibody Bioconjugates for Cancer Therapy.” ChemMedChem 3 (12) (December 15): 1839–1843. doi:10.1002/cmdc.200800122.
Research Data
Abstract
Affibodies are a class of polypeptide ligands that are potential candidates for cell- or tissue-specific targeting of drug-encapsulated controlled release polymeric nanoparticles (NPs). Here we report the development of drug delivery vehicles comprised of polymeric NPs that are surface modified with Affibody ligands that bind to the extracellular domain of the trans-membrane human epidermal growth factor receptor 2 (HER-2) for targeted delivery to cells which over express the HER-2 antigen. NPs lacking the anti-HER-2 Affibody did not show significant uptake by these cells. Using paclitaxel encapsulated NP-Affibody (1 wt% drug loading), we demonstrated increased cytotoxicity of these bioconjugates in SK-BR-3 and SKOV-3 cell lines. These targeted, drug encapsulated NPAffibody bioconjugates may be efficacious in treating HER-2 expressing carcinoma.
Description
Other Available Sources
Keywords
Affibody, Nanoparticle, PLA/PEG, Antitumor Agents, Targeted Therapy
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service